The Cardiologist Who Stopped Prescribing Statins Explains the Real Cause of Heart Attacks | Dr. Aseem Malhotra - ENCORE

What It Covers

UK cardiologist Dr. Aseem Malhotra explains why he stopped prescribing statins after discovering commercial distortions in cholesterol research, revealing how LDL obsession masks insulin resistance as heart disease's true driver while pharmaceutical trials systematically underreport side effects.

Key Questions Answered

• •Statin Efficacy Numbers: Treating 83 people with statins for five years prevents one death in high-risk patients who already had heart attacks. For primary prevention in those without heart disease, 100 people taking statins for five years prevents one nonfatal heart attack without extending life by a single day.
• •Trial Design Manipulation: Pharmaceutical companies remove patients experiencing side effects during pre-randomization run-in phases before trials officially begin, then report results only from remaining participants. The Heart Protection Study eliminated one-third of volunteers for noncompliance before starting, systematically underreporting adverse effects to maximize drug sales.
• •LDL Cholesterol Paradox: Framingham data shows LDL below 250 mg/dL has no predictive value for coronary disease when corrected for triglycerides and HDL. Systematic review of 30 cholesterol-lowering drug trials found no consistent relationship between LDL reduction and cardiovascular event prevention, even in high-risk patients.
• •Heart Attack Lipid Profile: Analysis of 231,000 heart attack patients across 541 hospitals revealed 75% had normal LDL under 130, while 50% had optimal levels under 100. The distinguishing factor was metabolic dysfunction with average HDL of 39 and triglycerides of 160, indicating insulin resistance drives disease.
• •Familial Hyperlipidemia Management: Among FH patients with genetically high cholesterol, 50% of men and 70% of women never develop premature heart disease. When corrected for insulin resistance through normal waist circumference and low insulin levels achieved via diet, FH patients' cardiovascular risk drops nearly to baseline population levels.